Sustainability
A global pioneer in the development of new drugs
SK Biopharmaceuticals is fortifying ESG management to maximize corporate value.
We have established the ESG/Strategic Committee within the Board of Directors and set a goal of discussing at least 3 ESG-related
agendas for each year to rapidly and actively respond to risks and pursue opportunities associated with ESG.
Also, we have operated the ESG Secretariat, which reports directly to the CEO.
Safety·Health·Environment (SHE) Policy
-
Recognizing that Safety, Health and Environment are the basic factors for securing competitiveness in differentiated research activities,
we strive to continuously improve Safety, Health and Environment outcomes based on our strong execution power through SUPEX.
Application of Policy
This Policy is applied to all members, subsidiaries, and suppliers involved in SK Biopharmaceutical‘s corporate activities.
Management Organization of SHE
SK Biopharmaceuticals operates an ESG/Strategic Committee within the board of directors to promote the internalization of SHE management and its implementation throughout the organization.
Under the leadership of CEO and the Chief Technology Officer (CTO), who is appointed as the responsible person for safety and health management, the headquarters establishes and executes safety and health plans.
Furthermore, a dedicated department responsible for SHE management is designated and operated to facilitate the practical implementation of SHE management by SHE professionals.
Under the leadership of CEO and the Chief Technology Officer (CTO), who is appointed as the responsible person for safety and health management, the headquarters establishes and executes safety and health plans.
Furthermore, a dedicated department responsible for SHE management is designated and operated to facilitate the practical implementation of SHE management by SHE professionals.
Safety∙Health∙Environment Management
SHE (Safety, Health, Environment) operates a system, ensuring sound management of drug development
and Safety, Health, Environment.
-
Waste Management
- Establish waste control process
- Establishment of Zero Waste to Landfill (ZWTL) Goal
- Operate systematically by using RFID tags
- Manage warehouse for waste storage
-
Chemical Management
- Establish management for chemical materials and MSDS
- Conduct regular training of management process
- Build a system for the evaluation of environmental hazards of APIs
-
Safety Management for All Employees
- Conduct Annual Hazard and Operability Study
- Quarterly Operation of the Industrial Safety and Health Committee
- Monthly Operation of the Cooperative Partner Safety and Health Consultative Body
- Conduct Annual Emergency Response Training
2040 NET ZERO
SK Biopharmaceuticals recognizes climate change adaptation as an essential element of its management strategy and has declared the goal of achieving net zero greenhouse gas emissions by 2040, aiming to reach a net emissions level of zero by 2040.
This declaration is based on the '2040 Net Zero Roadmap,' which was formulated adopting the RCP-2.6 scenario used in the IPCC Fifth Assessment Report. The Roadmap has been supplemented with socio-economic elements using the SSP1-2.6(Shared Socioeconomic Pathways) scenario, as featured in the IPCC Sixth Assessment Report published in May 2022.
Through this, SK Biopharmaceuticals commits to actively participating in achieving low-emission scenarios, limiting global warming to 1.5 degrees Celsius, and planning and implementing practical mitigation measures.
This declaration is based on the '2040 Net Zero Roadmap,' which was formulated adopting the RCP-2.6 scenario used in the IPCC Fifth Assessment Report. The Roadmap has been supplemented with socio-economic elements using the SSP1-2.6(Shared Socioeconomic Pathways) scenario, as featured in the IPCC Sixth Assessment Report published in May 2022.
Through this, SK Biopharmaceuticals commits to actively participating in achieving low-emission scenarios, limiting global warming to 1.5 degrees Celsius, and planning and implementing practical mitigation measures.
Achievement Plan for Net Zero
Short-Term and Long-Term Key Initiatives
Indirect Greenhouse Gas Reduction Status (Recent 3-year)
| Company Name | Initiative Project Title | Reduction Amount | Performance Period |
|---|---|---|---|
| SK Biopharmaceuticals | RE100 (Green Premium Tariff) | 447 | 2021.07 ~ 2021.12 |
| SK Biopharmaceuticals | RE100 (Green Premium Tariff) | 436 | 2022.03 ~ 2022.12 |
| SK Biopharmaceuticals | RE100 (Green Premium Tariff) | 575 | 2023.01 ~ 2023.12 |
Environmental Management System
SK Biopharmaceuticals is committed to implementing an environmental management strategy with the goal of addressing climate change and minimizing environmental impact.
We strive not only for the well-being of our customers' health but also to contribute to a future society where everyone can live together in good health. We prioritize a sense of purpose that extends beyond the mere legal management of hazardous substances emitted outside our facilities.
We are committed to fulfilling our social role and, in addition to complying with relevant laws, we operate with the aim of minimizing the environmental impact on the local community.
To achieve this, we have established short-term and long-term reduction goals for the proper management of hazardous substances, moving beyond legal compliance to further minimize their impact on the environment in the community.
We strive not only for the well-being of our customers' health but also to contribute to a future society where everyone can live together in good health. We prioritize a sense of purpose that extends beyond the mere legal management of hazardous substances emitted outside our facilities.
We are committed to fulfilling our social role and, in addition to complying with relevant laws, we operate with the aim of minimizing the environmental impact on the local community.
To achieve this, we have established short-term and long-term reduction goals for the proper management of hazardous substances, moving beyond legal compliance to further minimize their impact on the environment in the community.
Short-Term/Long-Term Reduction Goal Roadmap for Environmental Hazardous Substance
1) Short-Term Reduction Goal(~2025)
| Core Objective | Performance in 2022 | Plans for 2023 |
|---|---|---|
|
· A 1% annual reduction in hazardous substance emissions by 2025 |
· In 2022, the generated waste amount was approximately 41.8 tons, achieving a reduction of around 10% compared to the target of 46.3 tons |
· Setting a target of 41.4 tons for waste generation in 2023, aiming for a reduction of approximately 1% compared to 2022 |
2) Long-Term Reduction Goal(~2035) : Reduction rate of hazardous substance emissions intensity compared to the previous year
| Classification | Unit | Reduction Target (~2026) |
Reduction Target (~2028) |
Reduction Target (~2030) |
Reduction Target (~2035) |
|---|---|---|---|---|---|
| Air Pollutants | % | -44 | -56 | -66 | -80 |
| Water Pollutants | % | -44 | -53 | -62 | -74 |
| Waste Disposal Amount | % | -41 | -50 | -58 | -71 |
※ Intensity (kg/one billion won) =Hazardous substance emissions (kg) / Revenue from products and other sources(one billion won)
Safety·Health Management System
SK Biopharmaceuticals recognizes that workplace safety and health issues are critical concerns that can directly result in human harm.
Under the leadership of the Safety and Health team, we hold industry safety and health committee meetings at least once every quarter to actively solicit and manage members' opinions on safety and health matters. Furthermore, we have established an employee and partner company occupational management system to achieve our three-year long-term goals for advancing safety and health management excellence, in alignment with enhancing safety and health management practices.
Under the leadership of the Safety and Health team, we hold industry safety and health committee meetings at least once every quarter to actively solicit and manage members' opinions on safety and health matters. Furthermore, we have established an employee and partner company occupational management system to achieve our three-year long-term goals for advancing safety and health management excellence, in alignment with enhancing safety and health management practices.
Roadmap for Advancing Safety and Health Management System
| Classification | Phase1 (2023) | Phase2 (2024) | Phase3 (2025) |
|---|---|---|---|
| Goals for Advancing Safety Management System |
· Enhancement of Compliance System for the Act on Punishment of Major Accidents · Establishment of a Supplier Registration Evaluation System |
· Enhancing the Participation Environment for Member Safety and Health · Establishment of Supplier Selection and Evaluation System |
· Continual Improvement of Member-Driven Safety and Health Management System · Enhancement of SHE Management System for Partner Companies |
| Goals for Advancing Health Management System |
· Foundation Survey for Health Management System Implementation · Confined Space Health Program Establishment |
· Establishment of Health Management System Implementation Strategies · Enhancement of Confined Space Health Program |
· Implementation of Health Management System Policy and Programs · Evaluation of Confined Space Health Program |
Operation of Safety/Health/Environmental Management System
SK Biopharmaceuticals holds safety and health management systems as well as environmental management systems for its domestic and
international facilities, including research facilities at its headquarters in Korea. In accordance with international standards, the company conducts
regular safety, health, and environmental compliance audits to assess the adherence to regulatory requirements and compliance. These efforts
contribute to the continuous improvement of the SHE (Safety, Health, and Environment) management systems.
Safety, Health, and Environmental Management Certification Status
| Classification | Certification Scope | Registration Date | Certification Agency |
|---|---|---|---|
| ISO 45001 (Safety & Health Management System) |
Headquarters : Development of new medicine (Completed 100% : 1 out of 1 site) |
2023.5.11 | LRQA (Lloyd's Register Quality Assurance) |
| ISO 14001 (Environment Management System) |
2022.5.23 | KFQ (Korean Foundation for Quality) |
Compliance Audit Status for SHE Management
| Classification | Audit Cycle | Audit Leading Department |
|---|---|---|
| Initial Stage 1+2 | Initial One-time | External Audit Agency (LRQA, KFQ) |
| Internal Audit | Once a year | SHE Team |
| Surveillance | Once a year | External Audit Agency (LRQA, KFQ) |
| Re-Certification | Once every 3 years | External Audit Agency (LRQA, KFQ) |
Safety&Health and Environmental Management Certification
-
ISO 45001(Safety & Health Management System)
-
ISO 14001 (Environment Management System)